Selection and Qualification of Simplified QSP Models When Using Model Order Reduction Techniques

Quantitative systems pharmacology (QSP) models are increasingly used in drug development to provide a deep understanding of the mechanism of action of drugs and to identify appropriate disease targets. Such models are, however, not suitable for estimation purposes due to their high dimensionality. Based on any desired and specific input-output relationship, the system may be reduced to a model with fewer states and parameters. However, any simplification process will be a trade-off between model performance and complexity. In this study, we develop a weighted composite criterion which brings together the opposing indices of performance and dimensionality. The weighting factor can be determined by qualification of the simplified model based on a visual predictive check (VPC) using the precision of each parameter. The weighted criterion and model qualification techniques were illustrated with three examples: a simple compartmental pharmacokinetic model, a physiologically based pharmacokinetic (PBPK) example, and a semimechanistic model for bone mineral density. When considering the PBPK example, this automated search identified the same reduced model which had been detected in a previous report, as well as a simpler model which had not been previously identified. The simpler bone mineral density model provided an adequate description of the response even after 1 year from the initiation of treatment. The proposed criterion together with a VPC provides a natural way for model order reduction that can be fully automated and applied to multiscale models.

[1]  L. Aarons,et al.  Proper lumping in systems biology models. , 2009, IET systems biology.

[2]  Masoud Jamei,et al.  Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance , 2016, Current Pharmacology Reports.

[3]  A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  V. Chernick,et al.  Remodeling , 2006 .

[5]  Matthew M Riggs,et al.  A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.

[6]  O Demin,et al.  Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors , 2013, CPT: pharmacometrics & systems pharmacology.

[7]  B Ribba,et al.  Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation , 2017, CPT: pharmacometrics & systems pharmacology.

[8]  P Chan,et al.  Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance , 2013, CPT: pharmacometrics & systems pharmacology.

[9]  Leon Aarons,et al.  Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data , 2015, The AAPS Journal.

[10]  Leon Aarons,et al.  Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  M. Rashid,et al.  A mechanistic model for internal bone remodeling exhibits different dynamic responses in disuse and overload. , 2001, Journal of biomechanics.

[12]  Leon Aarons,et al.  Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.

[13]  William L. Goffe,et al.  SIMANN: FORTRAN module to perform Global Optimization of Statistical Functions with Simulated Annealing , 1992 .

[14]  S B Duffull,et al.  Scale Reduction of a Systems Coagulation Model With an Application to Modeling Pharmacokinetic–Pharmacodynamic Data , 2014, CPT: pharmacometrics & systems pharmacology.

[15]  V Shivva,et al.  An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models , 2013, CPT: pharmacometrics & systems pharmacology.

[16]  Thomas J. Snowden,et al.  A combined model reduction algorithm for controlled biochemical systems , 2017, BMC Systems Biology.

[17]  R. Eastell,et al.  Cancellous bone remodeling in type i (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[19]  Chihiro Hasegawa,et al.  Exploring inductive linearization for pharmacokinetic–pharmacodynamic systems of nonlinear ordinary differential equations , 2018, Journal of Pharmacokinetics and Pharmacodynamics.

[20]  Neil Benson,et al.  Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology , 2013, Interface Focus.

[21]  Thomas J. Snowden,et al.  Methods of Model Reduction for Large-Scale Biological Systems: A Survey of Current Methods and Trends , 2017, Bulletin of Mathematical Biology.

[22]  T. Wajima,et al.  A Comprehensive Model for the Humoral Coagulation Network in Humans , 2009, Clinical pharmacology and therapeutics.

[23]  MC Peterson,et al.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.

[24]  Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[26]  P. Pickkers,et al.  Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers , 2016, Clinical Pharmacokinetics.

[27]  Janet R. Wade,et al.  A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective , 2005, The AAPS Journal.

[28]  Wilhelm Huisinga,et al.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models , 2010, Journal of Pharmacokinetics and Pharmacodynamics.